IP Library Granted Patent US 10,906,904
Granted Patent B2
US 10,906,904 · App. 15/201,969 · Granted Feb 2, 2021

ADO-resistant cysteamine analogs and uses thereof

Inventors: Todd C. Zankel (Novato, CA); John Unitt (Nottingham, GB); Timothy Phillips (Nottingham, GB); Benoit Gourdet (Nottingham, GB); Lorna Duffy (Nottingham, GB)
Assignee: HORIZON ORPHAN LLC
C07D471/08A61K31/145A61K31/397A61K31/40A61K31/4402A61K31/445A61K31/4409A61K31/4465C07C323/25C07C323/26C07C323/30C07D205/04C07D207/08C07D211/54C07D211/60C07D213/32C07D213/70C07D223/06C07D295/088C07D451/04C07C2601/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,906,904
App. No.
15/201,969
Granted
Feb 2, 2021
Kind
B2
Abstract

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

Claims (19)

1. A method of treating a patient suffering from Huntington's Disease, Parkinson's Disease, concussion, stroke, and traumatic brain injury (CTE) comprising administering to the patient an effective amount of a composition comprising a compound of formula I or a disulfide thereof, wherein the compound of formula I is selected from the group consisting of:

wherein:

R 1 and R 2 are independently selected from the group consisting of H and C 1-5 alkyl; or

R 1 and R 2 , taken together with the carbon atom to which they are attached, form a 3-, 4-, 5-, 6-, 7-, or 8-membered carbocyclic ring;

R 3 and R 4 are independently selected from the group consisting of H and C 1-5 alkyl; or

R 3 and R 4 , taken together with the carbon atom to which they are attached, form a 3-, 4-, 5-, 6-, 7-, or 8-membered carbocyclic ring;

G is selected from the group consisting of —NR 5 R 6 and —CR 7 R 8 NR 5 R 6 ;

R 5 and R 6 are independently selected from the group consisting of H and C 1-5 alkyl; or

R 5 and R 6 , taken together with the nitrogen atom to which they are attached, form a 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclic ring;

R 7 and R 8 are independently selected from the group consisting of H and C 1-5 alkyl; or

R 7 and R 8 , taken together with the carbon atom to which they are attached, form a 3-, 4-, 5-, 6-, 7-, or 8-membered carbocyclic ring;

R 2 and R 6 , taken together with the atoms to which they are attached, form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocyclic ring;

R 4 and R 6 , taken together with the atoms to which they are attached, form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocyclic ring;

R 2 and R 8 , taken together with the atoms to which they are attached, form a 3-, 4-, 5-, 6-, 7-, or 8-membered carbocyclic ring; or

R 2 and R 4 , taken together with the atoms to which they are attached, form a 3-, 4-, 5-, 6-, 7-, or 8-membered carbocyclic ring;

with the proviso that when G is —NH 2 , at least one of R 1 , R 2 , R 3 , and R 4 is other than H.

2. The method of claim 1 , wherein the compound of formula I or disulfide thereof is resistant to metabolism by cysteamine dioxygenase (ADO).

3. The method of claim 1 , wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are independently selected from the group consisting of H and C 1-5 alkyl.

4. The method of claim 1 , wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are independently selected from the group consisting of H and methyl.

Assignments (7)
MERGER AND CHANGE OF NAME Recorded Dec 21, 2023
From: HORIZON THERAPEUTICS, LLC; HORIZON ORPHAN LLC
To: HORIZON THERAPEUTICS U.S. HOLDING LLC
Reel/Frame 065928/0608 →
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS U.S. HOLDING LLC (FKA RAPTOR PHARMACEUTICALS INC.)
Reel/Frame 065178/0955 →
CHANGE OF NAME Recorded Dec 20, 2016
From: RAPTOR PHARMACEUTICALS INC.
To: HORIZON ORPHAN LLC
Reel/Frame 041034/0782 →
SECURITY AGREEMENT Recorded Oct 26, 2016
From: RAPTOR PHARMACEUTICALS INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040479/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2016
From: UNITT, JOHN; PHILLIPS, TIMOTHY; GOURDET, BENOIT; DUFFY, LORNA
To: SYGNATURE DISCOVERY LIMITED
Reel/Frame 039272/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2016
From: ZANKEL, TODD C.
To: RAPTOR PHARMACEUTICALS INC.
Reel/Frame 039272/0308 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2016
From: SYGNATURE DISCOVERY LIMITED
To: RAPTOR PHARMACEUTICALS INC.
Reel/Frame 039272/0323 →
Continuity (3)
Provisional Application 62387337 · Dec 23, 2015
Provisional Application 62187939 · Jul 2, 2015
Related Publication 20170002004A1 · Jan 5, 2017